Praziquantel, (r)-
As of the edition of 20 October 2026, Praziquantel, (r)- is a small molecule: marketed, first approved in 2026 (BR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- First approved
- 30 September 2026 (BR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- FUNDAÇÃO OSWALDO CRUZ
- Registered trials
- 2, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2014 to now |